- Home
- PMNT vs NRXP Comparison
PMNT vs NRXP Comparison
Compare PMNT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMNT
- NRXP
- Stock Information
- Founded
- PMNT 1984
- NRXP 2015
- Country
- PMNT United Kingdom
- NRXP United States
- Employees
- PMNT N/A
- NRXP N/A
- Industry
- PMNT
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- PMNT
- NRXP Health Care
- Exchange
- PMNT NYSE
- NRXP Nasdaq
- Market Cap
- PMNT 14.6M
- NRXP 14.8M
- IPO Year
- PMNT 2024
- NRXP N/A
- Fundamental
- Price
- PMNT $1.00
- NRXP $1.52
- Analyst Decision
- PMNT Strong Buy
- NRXP Strong Buy
- Analyst Count
- PMNT 1
- NRXP 3
- Target Price
- PMNT $6.00
- NRXP $31.67
- AVG Volume (30 Days)
- PMNT 79.7K
- NRXP 288.4K
- Earning Date
- PMNT 11-14-2024
- NRXP 11-14-2024
- Dividend Yield
- PMNT N/A
- NRXP N/A
- EPS Growth
- PMNT N/A
- NRXP N/A
- EPS
- PMNT N/A
- NRXP N/A
- Revenue
- PMNT $22,375,000.00
- NRXP N/A
- Revenue This Year
- PMNT $3.91
- NRXP N/A
- Revenue Next Year
- PMNT $29.32
- NRXP N/A
- P/E Ratio
- PMNT N/A
- NRXP N/A
- Revenue Growth
- PMNT N/A
- NRXP N/A
- 52 Week Low
- PMNT $0.70
- NRXP $1.10
- 52 Week High
- PMNT $6.05
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- PMNT N/A
- NRXP 66.79
- Support Level
- PMNT N/A
- NRXP $1.17
- Resistance Level
- PMNT N/A
- NRXP $1.23
- Average True Range (ATR)
- PMNT 0.00
- NRXP 0.11
- MACD
- PMNT 0.00
- NRXP 0.04
- Stochastic Oscillator
- PMNT 0.00
- NRXP 58.57
About PMNT PERFECT MOMENT LTD
Perfect Moment Ltd is a company which is a luxury lifestyle brand that combines fashion and technical performance for its ranges of skiwear, outerwear, swimwear, and activewear. It operates at the intersection of luxury fashion and multi-channel commerce. Although the Company is organized fundamentally as one business segment which is product sales, the Company's revenues are primarily split between three geographic areas which are the U. S., Europe, and the UK.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.